Envudeucitinib Drug Asset Due Diligence Report 2026

This Envudeucitinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 3

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Envudeucitinib can convert its Small molecule drug profile and TYK2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Envudeucitinib (query alias: Envudeucitinib)
Modality / target	Small molecule drug; TYK2; TYK2 inhibitors
Highest global status	Phase 3
Originator	Fronthera U.S. Pharmaceuticals LLC
Active developers	Alumis, Inc.

The MCP disease footprint includes Plaque psoriasis, Systemic Lupus Erythematosus. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
JPRN-jRCT2071260031	Phase 3	募集中	16	Proportion of participants who achieved treatment response based on CGI-I (at Week 16)
NCT07378579	Phase 1	Completed	52	Change from baseline in placebo-adjusted QTcF (∆∆QTcF)
NCT06952634	Phase 1	Completed	32	Maximum observed plasma concentration (Cmax)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Phase 3; n=not disclosed; evaluation: Positive. Reported fields: sPGA 0/1(16-week): P-Value = <0.0001 Met; sPGA 0/1(16-week) = 59.0 % Met; sPGA 0/1(16-week): P-Value = <0.0001 Met

Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE study

Phase 2; n=165; evaluation: Positive. Reported fields: AE(discontinuation) = 3.7 %

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Phase 2; n=not disclosed; evaluation: Positive. Reported fields: PASI75 = 93 % Met

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Envudeucitinib addresses Plaque psoriasis, Systemic Lupus Erythematosus. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-03-25	Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan	Phase 3	US$40.0M upfront; US$140.0M milestones
2021-05-05	Esker acquires TYK2 inhibitor ESK-001 from Fronthera	Phase 1	Financial terms not disclosed
2021-03-09	海思科医药集团拟将其控股子公司FronThera U.S. Holdings Inc.的全部股权转让给FL2021-001, Inc.	Phase 1	US$60.0M upfront; US$120.0M milestones; US$180.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO